Journal
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
Volume 19, Issue 12, Pages 1057-1068Publisher
TAYLOR & FRANCIS AS
DOI: 10.1080/14737159.2020.1687295
Keywords
Cancer diagnostics; prognosis; predictive biomarkers; glycan microarrays; ELISA
Categories
Funding
- Slovak Research and Development Agency [APVV 17-0300]
- Ministry of Health of the Slovak Republic [2018/23-SAV-1]
- Qatar University [QUCG-CAM-19/20-2]
Ask authors/readers for more resources
Introduction: The review provides a comprehensive overview about applicability of serological detection of autoantibodies against aberrant glycans as cancer biomarkers. Areas covered: Clinical usefulness of autoantibodies as cancer biomarkers is discussed for seven types of cancers with sensitivity and specificity of such biomarkers provided. Moreover, an option of using serological antibodies against a non-natural form of sialic acid - N-glycolylneuraminic acid (Neu5Gc), which is taken into our bodies together with red meat, as a potential cancer biomarker is discussed shortly as well. Expert opinion: In the final part of the review, we discuss what measures need to be applied for selective implementation of autoantibody assays into a clinical practice. Moreover, we discuss key challenges ahead for reliable and robust detection of autoantibodies against aberrant glycans as biomarkers for disease diagnostics and for stratification of cancer patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available